[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,675,377
  • Shares Outstanding, K 107,593
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,800 K
  • EBIT $ -200 M
  • EBITDA $ -205 M
  • 60-Month Beta 0.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.26

Options Overview Details

View History
  • Implied Volatility 101.73% (-6.14%)
  • Historical Volatility 78.05%
  • IV Percentile 60%
  • IV Rank 25.26%
  • IV High 270.13% on 10/22/25
  • IV Low 44.82% on 06/26/25
  • Expected Move (DTE 17) 8.12 (20.56%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 518
  • Volume Avg (30-Day) 290
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 13,030
  • Open Int (30-Day) 12,292
  • Expected Range 31.37 to 47.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.51
  • Number of Estimates 7
  • High Estimate $-0.47
  • Low Estimate $-0.60
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.51 +30.07%
on 05/04/26
40.62 -2.30%
on 06/01/26
+9.08 (+29.65%)
since 05/01/26
3-Month
26.82 +47.95%
on 03/06/26
40.62 -2.30%
on 06/01/26
+9.25 (+30.37%)
since 02/27/26
52-Week
12.15 +226.63%
on 06/26/25
40.62 -2.30%
on 06/01/26
+25.41 (+177.91%)
since 05/30/25

Most Recent Stories

More News
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones —

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

BOULDER, Colo. , May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

–   Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up –

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 39.19 (+14.72%)
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

BOULDER, Colo. , March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present...

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

BOULDER, Colo. , March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular...

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 39.19 (+14.72%)
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

–  CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026  –

EWTX : 39.19 (+14.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 36.25
2nd Resistance Point 35.41
1st Resistance Point 34.79
Last Price 39.19
1st Support Level 33.33
2nd Support Level 32.49
3rd Support Level 31.87

See More

52-Week High 40.62
Last Price 39.19
Fibonacci 61.8% 29.74
Fibonacci 50% 26.38
Fibonacci 38.2% 23.03
52-Week Low 12.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.